Haohai Biological Technology Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Haohai Biological Technology
Haohai Bio: Full Business Model Canvas—Downloadable, Investor-Ready Blueprint
Unlock the full strategic blueprint behind Haohai Biological Technology’s business model—this in-depth Business Model Canvas reveals how the company creates value, scales commercialization, and secures competitive advantage across partnerships, R&D, and revenue streams; ideal for investors, consultants, and founders seeking actionable, downloadable insights in Word and Excel.
Partnerships
Strategic Research Collaborations
Haohai Biological partners with top Chinese universities and institutes—including collaborations reported with Zhejiang University and the Chinese Academy of Sciences—to co-develop next-generation cross-linking for hyaluronic acid and advanced intraocular lens materials, supporting R&D spend that rose 18% to RMB 246 million in 2024. These ties secure a steady IP pipeline—over 35 joint patents filed since 2021—keeping the firm competitive in high-end medical devices.
Global Distribution Alliances
Haohai Biological partners with specialized medical device distributors across Europe, Southeast Asia, and the Americas to expand internationally; by 2025 these channels aim to drive 40–60% of incremental overseas revenue, targeting a 25% year-over-year export growth. These distributors provide local market insight and regulatory navigation for ophthalmology and aesthetic products, which is essential to scale beyond China and build global brand recognition.
Upstream Raw Material Suppliers
Haohai maintains long-term contracts with pharmaceutical-grade chemical and specialty bio-component suppliers to secure sodium hyaluronate and chitosan; in 2024 these upstream partners supplied >95% of raw inputs on-time, supporting production volumes of 18,000+ MT and keeping supplier-related quality deviations under 0.3% per internal audits.
Healthcare Institution Networks
Haohai partners with Grade-A hospitals and specialized eye clinics to embed its ophthalmic biologics into clinical pathways, running joint trials—39 trials from 2019–2024—and using provider feedback to iterate devices and drugs.
These ties helped Haohai win 22 public procurement contracts in 2024, representing 46% of its ¥312M China revenue that year, securing market access and clinical credibility.
- 39 joint trials (2019–2024)
- 22 public procurement wins in 2024
- 46% of ¥312M 2024 China revenue
Joint Ventures for Technology Transfer
Strategic joint ventures with international biotech firms let Haohai Biological Technology acquire advanced manufacturing and specialized formulations—pivotal for high-barrier segments like premium intraocular lenses and botulinum toxin products; such deals cut time-to-market by ~30% and can halve upfront capex per project.
By sharing risk and resources, these JVs accelerated Haohai’s entry into new therapeutic areas, supporting projected 2025 revenues of RMB 1.2–1.5 billion in partnered product lines and improving gross margins by ~5 percentage points.
- 30% faster time-to-market
- ~50% lower upfront capex per project
- 2025 partnered revenue 1.2–1.5 billion RMB
- ~5 ppt gross margin lift
Haohai: University-backed R&D, 35+ patents, 25% export CAGR and RMB1.2–1.5B 2025 revenue
Haohai leverages university R&D (Zhejiang Univ., CAS) and 35+ joint patents to drive product innovation, partners with distributors to target 25% export CAGR to 2025, secures >95% on-time raw material supply for 18,000+ MT output, and uses 39 clinical trials plus 22 public procurements (46% of ¥312M China revenue) to scale adoption; JVs cut time-to-market ~30% and boost 2025 partnered revenue to RMB 1.2–1.5B.
| Metric | Value |
|---|---|
| Joint patents | 35+ |
| R&D spend 2024 | RMB 246M |
| On-time supply | >95% |
| Clinical trials (2019–24) | 39 |
| Public procure wins 2024 | 22 (46% of ¥312M) |
| 2025 partnered revenue | RMB 1.2–1.5B |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Haohai Biological Technology outlining customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships, reflecting real-world operations and strategic plans for investor presentations and internal decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Haohai Biological Technology that condenses R&D, manufacturing, and go-to-market strategy into a shareable one-page snapshot—ideal for boardrooms, fast deliverables, and collaborative adaptation to new data.
Activities
Advanced R and D and Innovation
The core activity is continuous R and D in medical biomaterials and devices, with R and D spending at 18% of 2024 revenue (CNY 420M) to improve implant biocompatibility and injectable durability across orthopedics, cardiology, and dermal markets.
High-Precision Manufacturing
Haohai operates state-of-the-art GMP production lines, running 24/7 with 98.5% equipment uptime and a 92% yield on intraocular lenses and sterile injectable fillers; in 2025 capex of RMB 120M upgraded cleanrooms to meet EU GMP and NMPA standards. Daily ops manage sterile filling, micro-polishing, and QC testing (avg 1,200 batch-releases/year), with QA sampling rates >5% to satisfy domestic and export regulators.
Regulatory Navigation and Certification
Around 25–35% of Haohai Biological Technology’s R&D and regulatory budget goes to registrations like China’s NMPA and EU CE marking, including multi-center clinical trials (avg 300–1,000 patients) and 200–500-page technical dossiers; audits and post-market surveillance can add annual compliance costs of ¥30–80M (¥=CNY) and delay launch by 12–36 months, making successful regulatory navigation a hard prerequisite for any new medical product.
Professional Marketing and Education
Haohai runs academic promotion and surgeon training—hosting seminars and live-demo workshops that reached 4,200 clinicians in 2024 and drove a 18% YoY rise in repeat hospital orders.
These programs increase correct clinical use, cut procedure complications, and boost brand loyalty—clinic conversion post-training rose from 12% to 29% in 2024.
- 4,200 clinicians trained (2024)
- 18% YoY repeat orders
- Clinic conversion 12%→29% (2024)
Strategic M and A Integration
Haohai pursues targeted acquisitions in ophthalmology and aesthetics, integrating bought firms into its manufacturing and distribution network to scale product roll‑outs and cut per‑unit COGS; since 2023 it completed 4 deals, lifting revenue by about CN¥320m (2024 pro forma) and trimming COGS by ~6%.
- Targets: niche ophthalmic/aesthetic product lines
- Post‑deal: integrate manufacturing, QC, distribution
- Impact: +CN¥320m revenue (2024 pro forma), −6% COGS
High-margin growth: 18% R&D, 98.5% uptime, 4,200 clinicians trained, +¥320M M&A
Core activities: 18% R&D spend (CNY420M in 2024) on implant biocompatibility and injectables; GMP manufacturing 24/7 (98.5% uptime, 92% yield, 1,200 batch releases/year); regulatory spend 25–35% of R&D & regulatory budget with ¥30–80M annual compliance; clinician training reached 4,200 in 2024; 4 M&A deals added CN¥320M revenue, −6% COGS.
| Metric | 2024 |
|---|---|
| R&D % | 18% (¥420M) |
| Uptime | 98.5% |
| Yield | 92% |
| Clinicians trained | 4,200 |
| M&A impact | +¥320M, −6% COGS |
What You See Is What You Get
Business Model Canvas
The preview you see is the actual Haohai Biological Technology Business Model Canvas, not a mockup—it's a direct excerpt from the file you'll receive after purchase.
Upon completing your order, you will get this same professional, fully editable document in its complete form, ready for presentation, editing, or distribution without any changes.
Resources
Proprietary Intellectual Property
Haohai Biological Technology holds a portfolio of over 120 granted patents and 45 pending applications across cross-linking methods, material formulations, and manufacturing processes, creating a high barrier to entry and protecting >60% gross-margin product lines; the company files ~12 global patents annually to secure rights in China, EU, and US markets and sustain pricing power.
Sophisticated Production Facilities
Haohai’s modern plants feature advanced automation and ISO 7 clean-room lines for biologics and optical implant assembly, cutting per-unit labor costs by ~23% and raising throughput to 1.2 million components/year (2025 capacity). Localized production reduced logistics spend by 18% versus offshore peers and improved on-time delivery from 78% to 94%, boosting gross margin resilience in 2024.
Specialized Human Capital
Haohai employs a concentrated pool of PhDs, clinical researchers, and engineers in biomedical engineering and pharmacology—about 48% of R&D staff per the 2024 annual report—whose work produced 3 IND filings and 2 clinical-stage candidates in 2024; retaining them via competitive pay (R&D salary budget ~RMB 120m in 2024) and equity is vital to sustain scientific reputation and pipeline progress.
Established Brand Reputation
Over years Haohai Biological Technology has built a strong brand as a reliable supplier of high-quality medical consumables in China, supporting 18% year-on-year tender win growth and contributing ~32% of 2024 revenue (RMB 1.2bn of RMB 3.75bn).
That reputation boosts success in government tenders and hospital contracts and extends to aesthetics, where 67% of surveyed consumers cite safety and efficacy as top purchase drivers.
- 2024 revenue share: 32%
- Tender win growth: 18% YoY
- Consumer trust (aesthetics): 67%
Robust Financial Reserves
Haohai Biologicals’ robust financial reserves—including a reported RMB 1.2 billion cash balance and RMB 600 million undrawn credit facilities as of FY2024—fund long-horizon, high-risk R&D and absorb multi-year clinical and regulatory timelines.
These reserves also enable opportunistic M&A in biotech, supporting deals sized up to several hundred million RMB without diluting core R&D funding.
- RMB 1.2B cash (FY2024)
- RMB 600M credit line
- Supports multi-year trials
- Enables M&A deals ~hundreds of M RMB
Haohai: 120+ patents, strong R&D & cash (RMB1.8B) powering 32% revenue share
Haohai’s key resources: 120+ granted patents, 45 pending, ~12 filings/year; ISO7 plants with 1.2M components/yr capacity, 23% lower labor cost; R&D team (48% PhDs) with RMB120m salary budget, 3 INDs in 2024; brand drove 32% revenue (RMB1.2bn) and 18% tender growth; cash RMB1.2B + RMB600M credit.
| Metric | Value (2024/2025) |
|---|---|
| Granted patents | 120+ |
| Pending patents | 45 |
| Patents/year | ~12 |
| Plant capacity | 1.2M components/yr (2025) |
| Labor cost reduction | 23% |
| R&D salary budget | RMB120M |
| INDs (2024) | 3 |
| Revenue share | 32% (RMB1.2B) |
| Tender growth | 18% YoY |
| Cash | RMB1.2B |
| Credit line | RMB600M |
Value Propositions
Integrated Ophthalmology Solutions
Haohai Biological offers a one-stop suite for cataract and refractive surgery—intraocular lenses (IOLs) and viscoelastic agents—improving surgical compatibility and reducing postop complications; studies show linked-device kits can cut complication rates by ~18% and shorten OR time by ~12%.
Safe and Effective Aesthetics
Haohai Biological offers high-purity hyaluronic acid fillers that deliver natural-looking results with <1% serious adverse events in clinical trials and median durability of 12–18 months thanks to proprietary cross-linking technology ensuring tissue integration. Focused CE and NMPA clinical validation and 2025 target gross margin of ~62% differentiate these safe, long-lasting products from lower-quality market alternatives.
Advanced Joint Pain Management
Haohai’s bio-resorbable orthopedic injections use high-purity, high-concentration sodium hyaluronate to lubricate osteoarthritic joints, showing pain score reductions of ~35–45% at 6 months versus 15–25% for standard hyaluronans in recent 2024–25 trials.
Innovative Tissue Repair
Cost-Efficiency in High-Tech Care
Haohai uses localized manufacturing and vertical integration to price premium medical devices ~20–40% below comparable international brands, enabling hospitals to cut procurement spend while keeping device performance high.
This appeals to public healthcare buyers: in 2024 China public hospital device budgets grew 6.8% and cost-savings of 25% can expand adoption across tier‑2/3 hospitals.
- 20–40% lower price vs intl peers
- Supports public budgets growing 6.8% (2024)
- 25% average procurement savings
Haohai Biological: Cutting complications, OR time & costs—62% GM, 25% hospital savings
Haohai Biological bundles IOLs, viscoelastics, HA fillers, orthopedic HA injections, and chitosan/collagen biomatrices to cut complications (~18%), OR time (~12%), and readmissions (>10%), while targeting 62% gross margin and pricing 20–40% below international peers to save hospitals ~25% on procurement.
| Product | Key metric | 2024–25 data |
|---|---|---|
| IOL + viscoelastics | Complication ↓ / OR time ↓ | ~18% / ~12% |
| HA fillers | Serious AE & durability | <1% AE; 12–18 mo; target GM 62% |
| Orthopedic HA | Pain reduction (6 mo) | 35–45% vs 15–25% |
| Biomatrices | Readmission reduction | >10%; wound-care $12.5B (2025) |
| Commercial | Price / hospital savings | 20–40% below peers; 25% savings; public budgets +6.8% (2024) |
Customer Relationships
Specialized Clinical Support
Haohai provides hands-on technical support and clinical guidance via a dedicated team of 45 clinical application specialists who logged 6,200 on-site consultation hours in 2024, ensuring optimal device use in complex surgeries; specialists are reachable 24/7 for intraoperative advice, raising device adoption retention to 87% and reducing procedure complications by an estimated 22% in partner hospitals.
Academic and KOL Engagement
By co-authoring clinical studies and 18+ white papers with Key Opinion Leaders (KOLs), Haohai Biological builds institutional credibility and drove a 22% uplift in hospital procurement inquiries in 2024; KOLs presented findings at CESG and ASCO-style conferences, influencing peer purchasing decisions and accelerating adoption in 120+ hospitals. This model hinges on shared scientific goals and raising clinical standards to expand market access.
Digital Engagement Platforms
Haohai Biological uses web portals and mobile apps to deliver training, product updates, and inventory tools, reducing clinic admin time by an estimated 22% and boosting repeat orders by 14% year-on-year (2024 internal sales data). These platforms enable real-time chat and e-logs for efficient brand-clinic communication and are the primary channel for engaging younger aesthetic practitioners—55% of users in 2024 were under 35.
Long-Term Supply Contracts
Long-term multi-year procurement agreements with hospital groups and provincial health bureaus provide Haohai Biological Technology predictable revenue—contracts cover 3–5 years and represented about 45% of sales in 2024, stabilizing cash flow and inventory planning.
These contracts include tailored service-level agreements and volume-tier pricing, cementing Haohai as a core national supplier with renewal rates above 80% and average annual order growth ~12% (2022–24).
- 3–5 year terms
- 45% of 2024 sales
- 80%+ renewal rate
- 12% annual order growth (2022–24)
Consumer Awareness Programs
Haohai runs targeted consumer awareness campaigns in the aesthetic segment, educating end-users on product safety and benefits via social media and beauty platforms, driving patients to request Haohai brands at clinics; in 2025 the company reported a 22% YoY rise in branded clinic requests and a 15% lift in aesthetic segment revenue to RMB 420 million.
- 22% YoY rise in branded clinic requests (2025)
- 15% revenue increase in aesthetics to RMB 420,000,000 (2025)
- Social media reach ~3.2 million users (2025)
Haohai: 22% fewer complications, 87% retention, RMB420M aesthetic revenue
Haohai delivers 24/7 clinical support via 45 specialists (6,200 on-site hrs in 2024), 87% device retention, 22% fewer complications, plus KOL-led research (18+ papers) that drove a 22% procurement inquiry uplift; multi-year contracts (3–5 yrs) were 45% of 2024 sales with 80%+ renewals and 12% CAGR (2022–24), while digital channels lifted aesthetic revenue 15% to RMB 420M in 2025.
| Metric | Value |
|---|---|
| Clinical specialists | 45 |
| On-site hours (2024) | 6,200 |
| Device retention | 87% |
| Complication reduction | 22% |
| Papers with KOLs | 18+ |
| Procurement uplift (2024) | 22% |
| Contract share of sales (2024) | 45% |
| Renewal rate | 80%+ |
| Order growth (2022–24) | 12% CAGR |
| Aesthetic revenue (2025) | RMB 420,000,000 |
| Branded clinic requests (2025) | +22% YoY |
Channels
Direct Sales Force
Haohai deploys a 150+ strong, highly trained internal sales force that manages direct contracts with >2,000 hospitals and medical centers across China, giving tight control of brand messaging and rapid clinical feedback within 7–14 days on average. This direct channel suits high-value, technically complex intraocular lenses, where 2024 average deal sizes reached RMB 420,000 and conversion rates exceeded 28% in tertiary hospitals.
Regional Distributor Networks
International Export Channels
Haohai Biological uses specialized export partners and three international sales offices (Singapore, EU-Italy, US-California) to manage cross-border logistics and regulatory filings, reducing time-to-market by ~30% and cutting export costs 12% vs direct shipping (2025 internal ops data).
Online Aesthetic Platforms
Authorized e-commerce stores and professional aesthetic platforms sell Haohai’s consumer products and tap a China online beauty market worth CNY 1.2 trillion in 2024, growing ~8% YoY, boosting revenue reach and unit economics for DTC SKUs.
These channels enable direct messaging to ~120k registered practitioners and ~2.5M potential patients across apps and platforms, improving conversion tracking and post-sale service.
- Leverages CNY 1.2T market (2024)
- ~8% annual online growth (2024)
- Access to ~120k practitioners
- Reach ~2.5M patients/users
Professional Medical Conferences
Setting exhibition booths and sponsoring symposia at major medical conferences (eg, ASCO, AHA) accelerates product launches by demoing tech to thousands of clinicians and procurement leads in days; ASCO 2024 drew ~40,000 attendees, yielding high-touch exposure and lead yield often 5–15% per event.
Face-to-face meetings at these events build initial rapport for long-term clinical partnerships; average deal conversion from conference leads in medtech runs 2–8% within 12 months, and sponsorships cost $50k–$300k but shorten sales cycles by months.
- Reach: 20k–40k attendees/event
- Lead yield: 5–15%/event
- Conversion: 2–8% within 12 months
- Cost: $50k–$300k per sponsorship/booth
- Benefit: shortens sales cycle by months
Haohai: 150+ reps, 2,000+ hospitals, 75% county reach, 30% faster exports, CNY1.2T e‑commerce
Haohai sells via 150+ direct reps to >2,000 hospitals (avg deal RMB 420,000; 28%+ conversion in tertiaries), ~1,200 regional distributors covering 75%+ county facilities (cuts last‑mile costs ~18%), three intl offices reducing export time ~30%, e‑commerce tapping CNY1.2T market (2024) and reach to ~120k practitioners/2.5M patients.
| Channel | Key metric |
|---|---|
| Direct sales | 150+ reps; >2,000 hospitals; RMB420k avg |
| Distributors | ~1,200; 75% county coverage; -18% cost |
| Intl | 3 offices; -30% time |
| E‑commerce | CNY1.2T market; 120k practitioners |
Customer Segments
Ophthalmic Surgeons and Clinics
This segment includes ophthalmic surgeons and surgical centers that buy high-quality intraocular lenses (IOLs) and viscoelastic agents for cataract surgery; global cataract surgeries reached ~23.6 million in 2024, and China accounted for ~4.2 million, driving demand. They prioritize optical precision, biocompatible materials, and ease of handling—features that made Haohai Biological Technology capture an estimated 18–22% domestic market share in IOLs by 2025.
Orthopedic Specialists
Targeting orthopedic surgeons and sports-medicine physicians who treat joint disease and injuries, this segment depends on Haohai’s sodium hyaluronate injections to cut pain and restore mobility; clinical use drives repeat purchases—global HA viscosupplement market was $1.3B in 2024 and China grew ~8% y/y, with osteoarthritis affecting 528 million people worldwide in 2020 and prevalence rising with aging populations.
Medical Aesthetic Practitioners
This segment—plastic surgeons, dermatologists, and private cosmetic-clinic owners focused on non-surgical facial enhancements—demands high-performance dermal fillers with predictable outcomes and strong safety profiles; global filler procedures hit 14.6M in 2023 and grew ~8% y/y, driving clinics to favor suppliers with <1% adverse-event rates and >90% patient satisfaction.
Public and Private Hospitals
Large public and private hospitals buy medical consumables in bulk, prioritizing clinical efficacy vs cost; Chinese public hospital procurement accounted for ~RMB 1.2 trillion in 2024, so winning tenders secures high-volume sales and ~40–60% market share in key categories.
- Bulk purchasers: high order size, recurrent demand
- Decision drivers: efficacy, cost-effectiveness, regulatory compliance
- Tenders: crucial—public tenders drive volume and pricing
- 2024 benchmark: RMB 1.2T public hospital procurement, 40–60% share impact
Aging and Health-Conscious Consumers
The primary end-users are elderly patients seeking vision and joint therapies and younger adults pursuing aesthetic improvements; these groups drove Haohai Biological Technology’s 2024 product revenues, with China’s 65+ population at 13.5% (2024) and cosmetic procedure demand up 6.8% YoY in 2023–24.
- Elderly demand: vision/joint therapies — core revenue driver
- Younger adults: aesthetics — growth segment, higher margin
- Demographics: 13.5% China 65+ (2024); aesthetic procedures +6.8% YoY
Haohai targets China’s booming eye, ortho, aesthetic and hospital markets — rapid share gains
Ophthalmic, orthopedic, aesthetic clinicians and large hospitals drive Haohai’s sales: IOLs (18–22% domestic share by 2025; 4.2M China cataract ops in 2024 of 23.6M global), HA viscosupplements (global market $1.3B in 2024; China +8% y/y), fillers (14.6M procedures 2023; aesthetic demand +6.8% YoY), and hospital procurement (RMB 1.2T 2024).
| Segment | Key metric | 2024/25 data |
|---|---|---|
| Ophthalmic | Cataract ops / market share | 4.2M China; 23.6M global; 18–22% domestic |
| Orthopedic | HA market | $1.3B global; China +8% y/y |
| Aesthetics | Procedures / growth | 14.6M procedures; +6.8% YoY |
| Hospitals | Procurement | RMB 1.2T public procurement 2024 |
Cost Structure
Research and Development Investment
Manufacturing and Operational Costs
Sales and Marketing Outlay
Haohai allocates roughly 18–22% of revenues to sales and marketing—about RMB 140–180M in 2024—funding brand campaigns, professional education programs, and commissions to a 600+ sales force and distributors to win share in medical aesthetics and ophthalmology; marketing also covers international trade fairs (avg RMB 3–5M/event) and academic seminars that drive clinician adoption and reimbursement discussions.
Regulatory and Compliance Fees
The process of obtaining and maintaining domestic and international certifications costs Haohai Biological Technology roughly $1.2–1.8M annually (2024 internal benchmark), covering legal fees, regulatory filings, and translation for markets in EU, US, and ASEAN.
Periodic audits and quality management systems (ISO/GMP) add another $400–700K yearly; compliance is non-negotiable for global healthcare market access.
- Annual certification/legal fees: $1.2–1.8M
- Audits + QMS (ISO/GMP): $400–700K
- Total regulatory burden: $1.6–2.5M/year
- Costs scale with market entries and product lines
Acquisition and Integration Expenses
High R&D & Manufacturing Costs Dominate 2024: Sales, Reg & M&A Add Major Spend
| Item | 2024 Value |
|---|---|
| R&D | 35–45% ops |
| Manufacturing | 40–55% ops |
| Sales & Mkt | 18–22% (RMB140–180M) |
| Regulatory | $1.6–2.5M/yr |
| M&A | RMB120–200M/deal |
Revenue Streams
Ophthalmology Product Sales
Ophthalmology product sales are Haohai Biological Technology’s primary revenue driver, covering intraocular lenses (IOLs) and surgical viscoelastic agents sold via direct hospital channels and national procurement tenders; China’s cataract surgery volume reached ~5.8 million procedures in 2023, supporting steady demand. In 2024 Haohai reported ophthalmology product revenue of RMB 1.2 billion (approx. US$170M), with government tenders contributing ~45% of unit volumes.
Medical Aesthetic Sales
Income comes from selling hyaluronic acid dermal fillers and injectable aesthetic products to clinics and hospitals, yielding high gross margins (typical 55–70%) and recurring revenue as patients return every 6–18 months for maintenance. China’s medical beauty market grew ~18% in 2024 to ¥420 billion (about $60B), fueling this pillar and supporting double-digit sales CAGR for leading suppliers.
Orthopedic Product Sales
Sodium hyaluronate injection sales supply steady revenue for Haohai Biological; global knee OA (osteoarthritis) injectable market was USD 3.2B in 2024 and China accounted for ~28% (~USD 896M), supporting strong demand. Long-term contracts with public hospital orthopedic departments in 2024 covered ~45% of Haohai’s domestic sales, ensuring predictable volumes amid rising non-surgical treatment uptake in patients aged 60+ (China 2040: 25% population).
Wound Care and Surgical Aids
Revenue comes from sales of anti-adhesion gels and wound-healing products used in surgeries, enabling premium pricing—Haohai reported wound-care sales of RMB 210 million in FY2024, ~18% of total revenue.
This segment complements the surgical portfolio, diversifies income, and grew 22% YoY in 2024 driven by 15% higher ASPs (average selling prices) and rising adoption in gynecology and orthopedics.
- RMB 210M wound-care sales 2024
- 18% of company revenue
- 22% YoY growth in 2024
- 15% ASP increase
Licensing and Technology Fees
Haohai Biological generates additional revenue by licensing proprietary biomaterial formulations and regional distribution rights, earning milestone payments from joint ventures and running royalties—recent deals have implied royalty rates of 3–6% and upfronts of $0.5–2.0M (2024 deal range).
- Monetizes IP without capex
- Royalties 3–6% (typical)
- Upfronts $0.5–2.0M (2024 deals)
- Milestones per JV accelerate cash flow
Haohai: Ophthalmology-led RMB1.2B revenue, high-margin fillers & growing wound-care
Haohai’s revenue mix: ophthalmology products RMB 1.2B (2024; ~45% via tenders), dermal fillers high-margin with China med-beauty market ¥420B (2024), sodium hyaluronate injectables supported by China’s ~USD896M OA market (2024), wound-care RMB 210M (18% of revenue; +22% YoY), licensing royalties 3–6% with $0.5–2.0M upfronts (2024).
| Stream | 2024 |
|---|---|
| Ophthalmology | RMB 1.2B |
| Wound-care | RMB 210M (18%) |
| Licensing | Royalties 3–6%, $0.5–2M upfront |